Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.03.2024 | Case report

Interferon-alpha-2a/ipilimumab/nivolumab

Various toxicities

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Weilandt J, et al. Chemotherapy Following Progression after Immune Checkpoint Inhibition in Metastasizing Malignant Melanoma: Case Report and Literature Review. [German] TumorDiagnostik und Therapie 44 : 625-631, No. 9, Nov 2023. Available from: URL: https://dx.doi.org/10.1055/a-2178-6146 [summarised from a translation] Weilandt J, et al. Chemotherapy Following Progression after Immune Checkpoint Inhibition in Metastasizing Malignant Melanoma: Case Report and Literature Review. [German] TumorDiagnostik und Therapie 44 : 625-631, No. 9, Nov 2023. Available from: URL: https://​dx.​doi.​org/​10.​1055/​a-2178-6146 [summarised from a translation]
Metadaten
Titel
Interferon-alpha-2a/ipilimumab/nivolumab
Various toxicities
Publikationsdatum
01.03.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-53778-9

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Various drugs

Case report

Nivolumab

Case report

Mesalazine

Case report

Multiple drugs

Case report

Deflazacort